← Back to Search

Behavioral Intervention

Sugary Drink Ban + Counseling for Metabolic Health Improvement (MHIP Trial)

N/A

Recruiting

Led By Laura A Schmidt, Ph.D

Research Sponsored by University of California, San Francisco

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up baseline and 12 months

Awards & highlights

MHIP Trial Summary

This trial is testing if banning sugary drinks in hospitals and counselling employees can improve their health.

Who is the study for?

This trial is for full-time employees at certain Sutter Health sites who drink three or more sugary drinks a week, can speak and read English, and are willing to have two fasting blood tests. Pregnant individuals cannot participate.Check my eligibility

What is being tested?

The study examines the effects of not selling sugary drinks (SSBs) at work and giving motivational counseling on employee health, specifically focusing on insulin resistance and abdominal obesity.See study design

What are the potential side effects?

There may be minimal side effects from participating in this trial as it involves lifestyle changes rather than medication. However, some participants might experience cravings or withdrawal symptoms from reducing sugar intake.

MHIP Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ baseline and 12 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~baseline and 12 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and 12 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Change in Abdominal Adiposity (Waist Circumference)

Change in Insulin Sensitivity (HOMA)

Secondary outcome measures

Change in ApoB Levels

Change in Body Mass Index (BMI)

Change in Fasting Glucose Levels

+3 more

Other outcome measures

Change in HbA1C Levels

Change in Uric Acid Levels

MHIP Trial Design

4Treatment groups

Experimental Treatment

Active Control

Group I: Workplace SSB sales ban onlyExperimental Treatment1 Intervention

Participants receive a workplace SSB sales ban (environmental intervention). This entails the removal of SSBs from all workplace sales outlets, replacing them with non-sugary beverage options.

Group II: Multilevel Intervention (workplace SSB sales ban + brief intervention)Experimental Treatment2 Interventions

Sales ban: Participants receive a workplace SSB sales ban (environmental intervention). This entails the removal of SSBs from all workplace sales outlets, replacing them with non-sugary beverage options. Brief Intervention: Participants receive a 20-30 minute intervention by video call, with 2 booster telephone calls. One week and one month after the initial session, participants will have 10-minute check-in/booster phone calls.

Group III: Brief intervention onlyExperimental Treatment1 Intervention

Participants receive a 20-30 minute intervention by video call, with 2 booster telephone calls. One week and one month after the initial session, participants will have 10-minute check-in/booster phone calls.

Group IV: Control: No workplace SSB sales ban, no brief interventionActive Control1 Intervention

Participants receive no workplace SSB sales ban (environmental intervention) and no brief counseling intervention.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Brief Intervention

2008

Completed Phase 3

~5860

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Sutter HealthOTHER

21 Previous Clinical Trials

156,200 Total Patients Enrolled

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NIH

2,359 Previous Clinical Trials

4,313,892 Total Patients Enrolled

California Pacific Medical Center Research InstituteOTHER

43 Previous Clinical Trials

11,826 Total Patients Enrolled

Media Library

Brief Intervention (Behavioral Intervention) Clinical Trial Eligibility Overview. Trial Name: NCT05972109 — N/A

Abdominal Obesity Research Study Groups: Multilevel Intervention (workplace SSB sales ban + brief intervention), Control: No workplace SSB sales ban, no brief intervention, Workplace SSB sales ban only, Brief intervention only

Abdominal Obesity Clinical Trial 2023: Brief Intervention Highlights & Side Effects. Trial Name: NCT05972109 — N/A

Brief Intervention (Behavioral Intervention) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05972109 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any available slots for test subjects in this experiment?

"Currently, this clinical trial is not accepting any more participants. Originally posted on August 1st 2023 and last edited nearly a month ago, the 182 other medical studies are actively recruiting patients for their trials."

Answered by AI

What is the primary goal of this clinical investigation?

"The primary outcome of the clinical trial will be gauged over a 12-month period and will measure any changes in insulin sensitivity (HOMA). Secondary outcomes include determining if there is an alteration in SSB intake, lipid profile measurements such as HDL, LDL, total cholesterol, triglycerides and their respective ratios; additionally, the team will also monitor ApoB blood levels. All metrics are measured at baseline and post 12 months."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Metabolic Health Improvement Program: Effects of a Workplace Sugary Beverages Sales Ban and Motivational Counseling

2023. "Metabolic Health Improvement Program: Effects of a Workplace Sugary Beverages Sales Ban and Motivational Counseling". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05972109.